It protected against NAFLD-HCC by secreting the antitumor metabolite acetate, which reached the liver via the portal vein and inhibited the interleukin 6 (IL-6)/Janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) signaling pathway [27]. Here, JAK1 is linked to hepatocellular carcinoma.